XTANDI is a prescription medicine used to treat men with prostate cancer that:

  • no longer responds to a hormone therapy or surgical treatment to lower testosterone
  • OR

  • has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone

It is not known if XTANDI is safe and effective in females or children.

Pay as little as
$0 per month.

See if you're eligible >

It's all about
having a game
plan

XTANDI can slow advanced prostate cancer progression.

XTANDI is a prescription medicine used to treat men with prostate cancer that no longer responds to a hormone therapy or surgical treatment to lower testosterone OR has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone. It is not known if XTANDI is safe and effective in females or children.


XTANDI is FDA-approved to treat 3 forms of advanced prostate cancer.

61%
LOWER
CHANCE

Metastatic castration-sensitive prostate cancer (mCSPC)

In a study with 1,150 men where the cancer had spread to other parts of the body and still responded to treatment to lower testosterone, XTANDI lowered the chance of progression by 61%.

The median* length of time until the cancer got worse was not reached for XTANDI + ADT** vs. 19 months for ADT alone.

Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason.

The trial is ongoing to determine effect on overall survival.

83%
LOWER
CHANCE

Metastatic castration-resistant prostate cancer (mCRPC)

In a study with 1,717 men where the cancer had spread to other parts of the body and no longer responded to treatment to lower testosterone, XTANDI lowered the chance of progression by 83%.

The median length of time until the cancer got worse was not reached for XTANDI + ADT vs. 4 months for ADT alone.

Progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason.

71%
LOWER
CHANCE

Non-metastatic castration-resistant prostate cancer (nmCRPC)

In a study with 1,401 men where the cancer had not spread to other parts of the body and no longer responded to treatment to lower testosterone, XTANDI lowered the chance of progression by 71%.

The median length of time until the cancer spread was 37 months for XTANDI + ADT vs. 15 months for ADT alone.

Progression was defined as the cancer spreading, as measured by scans, or if the patient died for any reason.

Results may vary. Talk with your doctor about what this may mean for you.

*The median is not the average but the middle of a set of numbers.

**ADT=Androgen Deprivation Therapy.

Select Safety Information

XTANDI may cause serious side effects, including seizure. If you take XTANDI, you may be at risk of having a seizure. Avoid activities where a sudden loss of consciousness could seriously harm you or someone else. Tell your doctor right away if you lose consciousness or have a seizure.

Stay informed

Whether you’re a patient or caregiver, you’re not fighting alone. We’re here for you with tools, tips, information, and support.

Ken, an XTANDI patient, and
Pat, his wife and caregiver.
XTANDI® (enzalutamide) patient and caregiver
XTANDI® (enzalutamide) Copay Card

Copay Assistance for Commercially Insured Patients

The XTANDI Patient Savings Program* is for eligible patients who have commercial prescription insurance.

Copay Assistance for Commercially Insured Patients

The XTANDI Patient Savings Program* is for eligible patients who have commercial prescription insurance.

XTANDI® (enzalutamide) Copay Card


*By enrolling in the XTANDI Patient Savings Program ("Program"), you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions: The Program is for eligible patients with commercial prescription insurance for XTANDI. The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Patients who move from commercial insurance to federal or state health insurance will no longer be eligible, and agree to notify the Program of any such change. Patients agree not to seek reimbursement from any health insurance or third party for all or any part of the benefit received by the patient through the Program. This offer is not conditioned on any past, present, or future purchase of XTANDI. This offer is not transferrable and cannot be combined with any other offer, free trial, prescription savings card, or discount. This offer is not health insurance and is only valid for patients in the 50 United States, Washington DC, Puerto Rico, Guam and Virgin Islands. This offer is not valid for cash paying patients. This Program is void where prohibited by law. No membership fees. It is illegal to sell, purchase, trade, counterfeit, duplicate, or reproduce, or offer to sell, purchase, trade, counterfeit, duplicate, or reproduce the card. This offer will be accepted only at participating pharmacies. Certain rules and restrictions apply. Astellas reserves the right to revoke, rescind, or amend this offer without notice.

Patient stories

Ken faces his diagnosis head-on with the support of his wife, Pat. Watching his children and grandchildren motivates him to keep going.

“After the initial shock, we pulled ourselves together and looked for our plan of attack.”

— Ken, an XTANDI patient.

This shows bottom of video container

You are now leaving XTANDI.com

The website you are about to visit is not owned or controlled by Astellas or Pfizer. Astellas and Pfizer are not responsible for the information or services on this site.

You are now leaving XTANDI.com

Please verify that you are a U.S. Healthcare Professional.

This information is intended for U.S. Healthcare Professionals only.

Are you a U.S. Healthcare Professional?